Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ProKidney
Biotech
ProKidney cell therapy wins half of trial, falls short on other
ProKidney’s cell therapy for kidney disease failed to demonstrate a clinically significant preservation of kidney function in one part of the study.
James Waldron
Jul 8, 2025 8:00am
ProKidney halts ph. 3 trial not needed for cell therapy approval
Sep 3, 2024 8:55am
Stanford president resigns—Chutes & Ladders
Jul 21, 2023 9:30am
CVS partners with ProKidney to enroll patients for phase 3 trial
Feb 2, 2023 8:10am
ProKidney’s $825M SPAC merger tees up cell therapy phase 3
Jan 18, 2022 8:35am
